Literature DB >> 44941

Importance of colicinogeny for the course of acute bacillary dysentery.

J Bures, V Horák, J Duben.   

Abstract

The development of acute bacillary dysentery was followed in 23 patients involved in two outbreaks and in three sporadic, mutually unrelated cases. Repeated cultivations performed at 2-day intervals for 10 days yielded 386 identifiable strains of "opportune intestinal flora". Escherichia coli colicinogenic activity is one of the significant factors of gastrointestinal tract protection. The period of shigella excretion is significantly reduced (p less than 0.02) if an appropriate colicinogenic E. coli strain is present. Analysis of the results suggested a working hypothesis of differentiated approach to bacillary dysentery treatment in outbreaks. In the absence of a suitable colicinogenic flora neomycin therapy should be administered since it does not damage the natural colonizing flora (bacteroids, bifidobacters, aerobic lactobacilli); in the presence of a suitable colicinogenic flora, no antibiotic should be used as this would abolish the coli-flora.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 44941

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Orig A        ISSN: 0300-9688


  3 in total

1.  Identification of multiple-resistance (R) and colicinogeny (Col) plasmids in an epidemic Salmonella agona serotype in Rio de Janeiro.

Authors:  A C Vicente; D F de Almeida
Journal:  J Hyg (Lond)       Date:  1984-08

2.  Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle.

Authors:  Jan Bures; David Smajs; Jaroslav Kvetina; Miroslav Förstl; Jan Smarda; Darina Kohoutova; Martin Kunes; Jiri Cyrany; Ilja Tacheci; Stanislav Rejchrt; Jirina Lesna; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

3.  Fifty-four Shigella sonnei colicin types and their typing by specific indicator strains.

Authors:  V Horák
Journal:  Folia Microbiol (Praha)       Date:  1985       Impact factor: 2.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.